$AEHR

SCOTT GEOFFREY GATES sold $2.6M of AEHR (indirect holdings)

SCOTT GEOFFREY GATES (Director) sold 20,000 indirectly-held shares of AEHR TEST SYSTEMS (AEHR) at $131.51 ($2.63M total) on 2026-08-12.

Original reporting
SEC EDGAR · SCOTT GEOFFREY GATES
Published Aug 13, 2026, 9:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 10:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AEHR
Neutral
medium confidence
Mentioned
$AEHR
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AEHRNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, price, and post-transaction holdings. It may slightly pressure sentiment, but it is not a guidance, earnings, or operational catalyst.

02

Market read

Traders may monitor AEHR for follow-on insider activity, but the filing alone is unlikely to drive a durable repricing without additional company news.

03

What to watch

The article provides no context on total holdings, prior sale cadence, or whether the sale was for diversification or tax obligations, limiting signal strength.

Relevance 6/10Novelty 5/10Timing: after-hours/next-session following the Form 4 filing date (2026-08-13)

Background

The article is a SEC Form 4 insider transaction disclosure for AEHR Test Systems, filed by director Scott Geoffrey Gates.

Company-level read

Ticker impact

$AEHRNeutralMedium confidence
Context

AEHR director Scott Geoffrey Gates sold 20,000 shares in an open-market transaction valued at $2.63M, per a fresh Form 4 filing.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

This is a routine Form 4 insider sale with no 10b5-1 plan and no accompanying company-specific operational or financial disclosure in the text.

Market effects

No sector-wide read-through is provided; the disclosure is company-specific and small relative to typical sector flows.

None indicated.

None indicated.

Counterpoint

Insider sales can be pre-planned for liquidity or tax needs; the absence of a stated 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

  • AEHR Test Systems

    Company whose director insider sale is disclosed via Form 4.

  • Scott Geoffrey Gates

    Director reporting an open-market sale of AEHR shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AEHRMed

AEHR Stock Rides AI Order Wave Amid Volatility

Aehr Test Systems (AEHR) stock rose 13.28% following strong earnings and a positive outlook for semiconductor test demand. The company reported $50M in revenue, $18.8M in quarterly revenue, and a net income of $1.39M. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's role in AI production. The stock has shown volatility, with a recent drop of 9.5-10.5% in a single session. Insiders have sold shares but maintain significant holdings. AEHR is actively presenting a

$AEHRHigh

AEHR Stock Rallies As AI Orders And Wall Street Support Build

Aehr Test Systems (AEHR) stock rose 11.71% due to strong AI-related demand. The company reported $18.8M in revenue with a 35.3% gross margin. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's role in AI chip production. The company has a strong balance sheet and a $22M follow-on order from a major customer.

$AEHRHigh

AEHR Stock Rallies As AI Test Orders And Wall Street Support Grow

Aehr Test Systems (NASDAQ: AEHR) stock rose 11.73% on growing AI test demand. The company secured a $22M follow-on order for AI chip testing equipment. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's unique position in AI production testing. The stock has high volatility, with a strong balance sheet but negative EBIT margins.